Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SYNCOM FORMULATIONS Gains 8%; BSE HEALTHCARE Index Down 0.3%
Mon, 8 Jul 12:11

SYNCOM FORMULATIONS Gains 8%; BSE HEALTHCARE Index Down 0.3%Image source: DNY59/www.istockphoto.com

SYNCOM FORMULATIONS share price has zoomed 8% and is presently trading at Rs 13.8.

Meanwhile, the BSE HEALTHCARE index is at 38,114.1 (down 0.3%).

Among the top gainers in the BSE HEALTHCARE index today are MAX HEALTHCARE INSTITUTE (up 2.0%) and GLAND PHARMA (up 1.9%).

Divis Laboratories (down 3.1%) and CAPLIN POINT (down 2.7%) are among the top losers today.

Over the last one year, SYNCOM FORMULATIONS has moved up from Rs 7.6 to Rs 13.8, registering a gain of Rs 6.3 (up 83.0%).

On the other hand, the BSE HEALTHCARE index has moved up from 25,703.5 to 38,114.1, registering a gain of 48.3% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Glenmark Pharma (up 107.6%), Cadila Healthcare (up 104.1%) and Lupin (up 99.0%).

Dear Reader: If You Invest in Midcap Stocks, this is for You

What About the Benchmark Indices?

The BSE Sensex is at 79,897.2 (down 0.1%).

The top losers among the BSE Sensex today are Titan (down 4.0%) and MUNDRA PORT & SEZ (down 2.0%). The most traded stocks in the BSE Sensex are Tata Steel and ITC.

In the meantime, NSE Nifty is at 24,272.7 (down 0.2%). Titan and Divis Laboratories are among the top losers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,479.1 to 79,897.2, registering a gain of 14,418.2 points (up 22.0%).

SYNCOM FORMULATIONS Financial Update...

SYNCOM FORMULATIONS net profit fell 12.6% YoY to Rs 74 million for the quarter ended March 2024, compared to a profit of Rs 85 million a year ago. Net sales rose 22.3% to Rs 746 million during the period as against Rs 610 million in January-March 2023.

For the year ended March 2023, SYNCOM FORMULATIONS reported 1.4% increase in net profit to Rs 201 million compared to net profit of Rs 198 million during FY22. Revenue of the company grew 2.1% to Rs 2,243 million during FY23.

The current Price to earnings ratio of SYNCOM FORMULATIONS, based on rolling 12 month earnings, stands at 51.3.


Equitymaster requests your view! Post a comment on "SYNCOM FORMULATIONS Gains 8%; BSE HEALTHCARE Index Down 0.3%". Click here!